Knight Therapeutics (TSE:GUD) Sets New 12-Month High – Here’s Why

Knight Therapeutics Inc. (TSE:GUD) reached a new 52-week high on Monday . The company traded as high as C$8.91 and last traded at C$8.88, with a volume of 33668 shares trading hands. The stock had previously closed at C$8.61.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group set a C$9.50 price objective on Knight Therapeutics and gave the company a “buy” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Knight Therapeutics has an average rating of “Buy” and a consensus target price of C$9.50.

Knight Therapeutics Stock Up 7.0%

The company has a debt-to-equity ratio of 8.86, a current ratio of 2.32 and a quick ratio of 1.79. The company has a market capitalization of C$904.23 million, a P/E ratio of 153.50, a PEG ratio of -1,013.50 and a beta of -0.14. The company has a 50 day moving average of C$7.88 and a 200-day moving average of C$6.72.

Knight Therapeutics (TSE:GUD) last posted its earnings results on Thursday, May 7th. The company reported C$0.13 earnings per share (EPS) for the quarter. The company had revenue of C$147.59 million for the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%. As a group, equities analysts anticipate that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.